{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T21:08:08Z","timestamp":1766869688247,"version":"3.45.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Translational Autoimmunity"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.jtauto.2021.100083","type":"journal-article","created":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T09:32:43Z","timestamp":1610271163000},"page":"100083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab"],"prefix":"10.1016","volume":"4","author":[{"given":"Nicholas","family":"Agresti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob P.","family":"Lalezari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip P.","family":"Amodeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kabir","family":"Mody","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven F.","family":"Mosher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harish","family":"Seethamraju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott A.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nader Z.","family":"Pourhassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. David","family":"Sudduth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Bovinet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed E.","family":"ElSharkawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce K.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reejis","family":"Stephen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonah B.","family":"Sacha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen L.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth A.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kush","family":"Dhody","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2020","series-title":"Novel Coronavirus (2019-nCoV): Situation Report 1","author":"World Health Organization","key":"10.1016\/j.jtauto.2021.100083_bib1"},{"key":"10.1016\/j.jtauto.2021.100083_bib3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"year":"2020","series-title":"Of the Treasury","key":"10.1016\/j.jtauto.2021.100083_bib6"},{"issue":"1","key":"10.1016\/j.jtauto.2021.100083_bib7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13613-019-0540-9","article-title":"Formal guidelines: management of acute respiratory distress syndrome","volume":"9","author":"Papazian","year":"2019","journal-title":"Ann. Intensive Care"},{"issue":"7","key":"10.1016\/j.jtauto.2021.100083_bib8","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/jac\/dkaa114","article-title":"COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression","volume":"75","author":"Zhou","year":"2020","journal-title":"J.\u00a0Antimicrob. Chemother."},{"issue":"9","key":"10.1016\/j.jtauto.2021.100083_bib9","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jamacardio.2020.1834","article-title":"Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)","volume":"5","author":"Mercuro","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.jtauto.2021.100083_bib10","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.jtauto.2021.100083_bib12","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.jtauto.2021.100083_bib13","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72\u00a0\u200b314 cases from the Chinese center for disease control and prevention","volume":"323","author":"Wu","year":"2020","journal-title":"Jama"},{"issue":"20","key":"10.1016\/j.jtauto.2021.100083_bib14","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area","volume":"323","author":"Richardson","year":"2020","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.jtauto.2021.100083_bib15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1128\/MMBR.05015-11","article-title":"Into the eye of the cytokine storm","volume":"76","author":"Tisoncik","year":"2012","journal-title":"Microbiol. Mol. Biol. Rev."},{"issue":"8","key":"10.1016\/j.jtauto.2021.100083_bib16","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41587-020-0634-9","article-title":"Focus shifts to antibody cocktails for COVID-19 cytokine storm","volume":"38","author":"Harrison","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"19","key":"10.1016\/j.jtauto.2021.100083_bib17","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A\u00a0trial of lopinavir-ritonavir in adults hospitalized with severe covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"10","key":"10.1016\/j.jtauto.2021.100083_bib18","first-page":"994","article-title":"Remdesivir for the treatment of covid-19 - preliminary report","volume":"383","author":"Beigel","year":"2020","journal-title":"Reply, N Engl J Med"},{"issue":"19","key":"10.1016\/j.jtauto.2021.100083_bib19","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 Days in patients with severe covid-19","volume":"383","author":"Goldman","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"24","key":"10.1016\/j.jtauto.2021.100083_bib20","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jtauto.2021.100083_bib21","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jtauto.2021.100083_bib22","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.medmal.2020.03.006","article-title":"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection","volume":"50","author":"Molina","year":"2020","journal-title":"Med. Maladies Infect."},{"issue":"21","key":"10.1016\/j.jtauto.2021.100083_bib23","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1056\/NEJMoa2019014","article-title":"Hydroxychloroquine with or without azithromycin in mild-to-moderate covid-19","volume":"383","author":"Cavalcanti","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jtauto.2021.100083_bib24","first-page":"1","article-title":"Dexamethasone in hospitalized patients with covid-19 - preliminary report","author":"Horby","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"8","key":"10.1016\/j.jtauto.2021.100083_bib25","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"10","key":"10.1016\/j.jtauto.2021.100083_bib26","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1136\/annrheumdis-2020-218122","article-title":"Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study","volume":"79","author":"Della-Torre","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.jtauto.2021.100083_bib31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/15284336.2018.1452842","article-title":"PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection","volume":"19","author":"Dhody","year":"2018","journal-title":"HIV Clin. Trials"},{"issue":"10","key":"10.1016\/j.jtauto.2021.100083_bib32","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1128\/AAC.00086-10","article-title":"Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults","volume":"54","author":"Jacobson","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.jtauto.2021.100083_bib33","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1086\/592169","article-title":"Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults","volume":"198","author":"Jacobson","year":"2008","journal-title":"J.\u00a0Infect. Dis."},{"issue":"10","key":"10.1016\/j.jtauto.2021.100083_bib34","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/652190","article-title":"Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody","volume":"201","author":"Jacobson","year":"2010","journal-title":"J.\u00a0Infect. Dis."},{"issue":"4","key":"10.1016\/j.jtauto.2021.100083_bib35","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/COH.0000000000000479","article-title":"The return of PRO 140, a CCR5-directed mAb","volume":"13","author":"Thompson","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.jtauto.2021.100083_bib36","article-title":"A\u00a0Phase 2 study of leronlimab for mild to moderate coronavirus disease 2019 (COVID-19), A special ISIRV conference","author":"Seethamraju","year":"2020","journal-title":"Virtual Conference"},{"key":"10.1016\/j.jtauto.2021.100083_bib38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cyto.2018.02.018","article-title":"CCR5: established paradigms and new frontiers for a \u2019celebrity\u2019 chemokine receptor","volume":"109","author":"Scurci","year":"2018","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.jtauto.2021.100083_bib39","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1128\/JVI.75.2.579-588.2001","article-title":"Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140","volume":"75","author":"Trkola","year":"2001","journal-title":"J.\u00a0Virol."},{"issue":"8","key":"10.1016\/j.jtauto.2021.100083_bib40","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/s41587-020-0602-4","article-title":"COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis","volume":"38","author":"Chua","year":"2020","journal-title":"Nat. Biotechnol."},{"year":"2019","series-title":"EZH2 enhances expression of CCL5 to promote recruitment of macrophages and invasion in lung cancer","author":"Xia","key":"10.1016\/j.jtauto.2021.100083_bib41"},{"issue":"6","key":"10.1016\/j.jtauto.2021.100083_bib42","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jinf.2020.03.037","article-title":"The pathogenesis and treatment of the \u2019Cytokine Storm\u2019 in COVID-19","volume":"80","author":"Ye","year":"2020","journal-title":"J.\u00a0Infect."},{"key":"10.1016\/j.jtauto.2021.100083_bib43","first-page":"2020","article-title":"Targeting the catecholamine-cytokine axis to prevent SARS-CoV-2 cytokine storm syndrome","author":"Konig","year":"2020","journal-title":"medRxiv"},{"issue":"2","key":"10.1016\/j.jtauto.2021.100083_bib44","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1165\/ajrcmb.18.2.2822","article-title":"Expression of RANTES by normal airway epithelial cells after influenza virus A infection","volume":"18","author":"Matsukura","year":"1998","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"6","key":"10.1016\/j.jtauto.2021.100083_bib45","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1128\/JVI.80.6.2684-2693.2006","article-title":"Modeling the early events of severe acute respiratory syndrome coronavirus infection in vitro","volume":"80","author":"Yen","year":"2006","journal-title":"J.\u00a0Virol."},{"issue":"1","key":"10.1016\/j.jtauto.2021.100083_bib46","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.immuni.2008.05.011","article-title":"The chemokine receptor CCR5 plays a key role in the early memory CD8+ T cell response to respiratory virus infections","volume":"29","author":"Kohlmeier","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.jtauto.2021.100083_bib47","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jcrc.2017.07.025","article-title":"Accuracy of C - Reactive protein as a bacterial infection marker in critically immunosuppressed patients: a systematic review and meta-analysis","volume":"42","author":"de Oliveira","year":"2017","journal-title":"J.\u00a0Crit. Care"},{"issue":"6508","key":"10.1016\/j.jtauto.2021.100083_bib48","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc8511","article-title":"Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications","volume":"369","author":"Mathew","year":"2020","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.jtauto.2021.100083_bib49","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1517\/14728222.2013.837886","article-title":"Targeting CCL5 in inflammation","volume":"17","author":"Marques","year":"2013","journal-title":"Expert Opin. Ther. Targets"},{"issue":"5231","key":"10.1016\/j.jtauto.2021.100083_bib50","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1126\/science.7569902","article-title":"Activation of dual T cell signaling pathways by the chemokine RANTES","volume":"269","author":"Bacon","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.jtauto.2021.100083_bib52","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12985-016-0544-0","article-title":"Middle East Respiratory Syndrome Coronavirus (MERS-CoV) origin and animal reservoir","volume":"13","author":"Mohd","year":"2016","journal-title":"Virol. J."},{"issue":"6","key":"10.1016\/j.jtauto.2021.100083_bib53","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/infdis\/jiv380","article-title":"Middle East respiratory syndrome coronavirus efficiently infects human primary T lymphocytes and activates the extrinsic and intrinsic apoptosis pathways","volume":"213","author":"Chu","year":"2016","journal-title":"J.\u00a0Infect. Dis."},{"issue":"3","key":"10.1016\/j.jtauto.2021.100083_bib54","doi-asserted-by":"crossref","first-page":"868","DOI":"10.4049\/jimmunol.1401193","article-title":"Cutting edge: critical role for C5aRs in the development of septic lymphopenia in mice","volume":"194","author":"Grailer","year":"2015","journal-title":"J.\u00a0Immunol."},{"issue":"9371","key":"10.1016\/j.jtauto.2021.100083_bib55","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(03)13412-5","article-title":"Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study","volume":"361","author":"Peiris","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jtauto.2021.100083_bib56","first-page":"318","article-title":"Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19","volume":"81","author":"Liu","year":"2020","journal-title":"J.\u00a0Infect."}],"container-title":["Journal of Translational Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909021000034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909021000034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:33:19Z","timestamp":1762903999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589909021000034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":46,"alternative-id":["S2589909021000034"],"URL":"https:\/\/doi.org\/10.1016\/j.jtauto.2021.100083","relation":{},"ISSN":["2589-9090"],"issn-type":[{"type":"print","value":"2589-9090"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab","name":"articletitle","label":"Article Title"},{"value":"Journal of Translational Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtauto.2021.100083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100083"}}